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general practice
Abstract

Background: Electronic medical records are increasingly used for research with limited external validation of
their data. Objective: This study investigates the validity of electronic medical data (EMD) for estimating
diabetes prevalence in general practitioner (GP) patients by comparing EMD with national Bettering the
Evaluation and Care of Health (BEACH) data. Method: A "decision tree" was created using inclusion/
exclusion of pre-agreed variables to determine the prob-ability of diabetes in absence of diagnostic label,
including diagnoses (coded/free-text diabetes, polycystic ovarian syn-drome, impaired glucose tolerance,
impaired fasting glucose), diabetic annual cycle of care (DACC), hemoglobin (HbA1 >6.5%, and prescription
(metformin, other diabetes medications). Via SQL query, cases were identified in EMD of five Illawarra and
Southern Practice Network practices (30,007 active patients; from 2 years to January 2015). Patient-based
Supplementary Analysis of Nominated Data (SAND) sub-studies from BEACH investigating diabetes
prevalence (1172 GPs; 35,162 patients; November 2012 to February 2015) were comparison data. SAND
results were adjusted for number of GP encounters per year, per patient, and then age-sex standardised to
match age-sex distribution of EMD patients. Cluster-adjusted 95% confidence intervals (CIs) were calculated
for both datasets. Results: EMD diabetes prevalence (T1 and/or T2) was 6.5% (95% CI: 4.1-8.9). Following
age-sex standardisation, SAND prevalence, not significantly different, was 6.7% (95% CI: 6.3-7.1). Extracting
only coded diagnosis missed 13.0% of probable cases, subsequently identified through the presence of
metformin/other diabetes medications medications (*without other indicator variables; 6.1%), free-text
diabetes label (3.8%), HbA1c result* (1.6%), DACC* (1.3%), and diabetes medications* (0.2%). Discussion:
While complex, proxy variables can improve usefulness of EMD for research. Without their consideration,
EMD results should be interpreted with caution. Conclusion: Enforceable, transparent data linkages in EMRs
would resolve many problems with identification of diagnoses. Ongoing data quality improvement remains
essential.
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Abstract
Background: Electronic medical records are increasingly used for research with limited external validation of their data.
Objective: This study investigates the validity of electronic medical data (EMD) for estimating diabetes prevalence in
general practitioner (GP) patients by comparing EMD with national Bettering the Evaluation and Care of Health (BEACH)
data. Method: A “decision tree” was created using inclusion/exclusion of pre-agreed variables to determine the probability of diabetes in absence of diagnostic label, including diagnoses (coded/free-text diabetes, polycystic ovarian syndrome, impaired glucose tolerance, impaired fasting glucose), diabetic annual cycle of care (DACC), hemoglobin (HbA1c)
> 6.5%, and prescription (metformin, other diabetes medications). Via SQL query, cases were identified in EMD of five
Illawarra and Southern Practice Network practices (30,007 active patients; from 2 years to January 2015). Patient-based
Supplementary Analysis of Nominated Data (SAND) sub-studies from BEACH investigating diabetes prevalence (1172
GPs; 35,162 patients; November 2012 to February 2015) were comparison data. SAND results were adjusted for number
of GP encounters per year, per patient, and then age–sex standardised to match age–sex distribution of EMD patients.
Cluster-adjusted 95% confidence intervals (CIs) were calculated for both datasets. Results: EMD diabetes prevalence (T1
and/or T2) was 6.5% (95% CI: 4.1–8.9). Following age–sex standardisation, SAND prevalence, not significantly different,
was 6.7% (95% CI: 6.3–7.1). Extracting only coded diagnosis missed 13.0% of probable cases, subsequently identified
through the presence of metformin/other diabetes medications medications (*without other indicator variables; 6.1%),
free-text diabetes label (3.8%), HbA1c result* (1.6%), DACC* (1.3%), and diabetes medications* (0.2%). Discussion:
While complex, proxy variables can improve usefulness of EMD for research. Without their consideration, EMD results
should be interpreted with caution. Conclusion: Enforceable, transparent data linkages in EMRs would resolve many
problems with identification of diagnoses. Ongoing data quality improvement remains essential.
Keywords (MeSH)
electronic medical records; data quality; data accuracy; general practice; primary health care; health information
management

Introduction
At many levels of the Australian health system, electronic
medical records (EMRs) are being employed increasingly
for research purposes, as they are considered a timely and
cost-effective method of providing data compared to the
traditional techniques employed for structured prospective
research studies (Shephard et al., 2011). In the primary
medical care setting, commercial organisations, academic
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institutions, and government-funded not-for-profit organisations have formed collaborations with general practices
to receive extracted patient data for analyses, for a variety
of purposes (Mazza et al., 2016; MedicalDirector Research
& Data Analytics, 2017; MedicineInsight, 2016).
There are significant limitations that influence the usefulness of these data but these limitations are not commonly
addressed. There are more than eight different software
products in use by Australian general practices (Gordon
et al., 2016), all with different structures, having been
independently created with different database designs’.
None have enforceable, transparent direct linkages between
the diagnosed problems/conditions being managed and the
medications/other managements provided for these conditions. Clinicians are able to link clinical problems to medications but this is entirely elective, not always recorded
accurately and frequently left incomplete. There are no
nationally agreed and implemented standards, so these
products have unique structures, data elements, data definitions, and data labels. As they utilise disparate terminology and classification systems (if any), pooling of these
incompatible data is extremely problematic (Gordon
et al., 2016). The data extraction tools used to access these
data also have limitations (Liaw et al., 2013).
While the common use of extracted EMR data has introduced an implied “acceptability” for research, the validity
and reliability of data extracted using these proprietary
software products and extraction tools are unknown. Some
organisations acknowledge the limitations of unknown data
completeness and accuracy (Mazza et al., 2016; Merrifield
et al., 2017) but there is no published evidence of attempts
to validate extracted data.
In 2015, members of the Illawarra and Southern Practice
Network (ISPRN) commenced an investigation with the aim
of validating their pooled electronic medical data (EMD) by
comparing it with data from the Bettering the Evaluation and
Care of Health (BEACH) program (Britt et al., 2014). The
initial results showed some similarities in patient demographics (age and sex) and in prescribing distribution patterns (Barnett et al., 2017). As an extension of that work, the
current article describes the comparison of prevalence estimates for diabetes based on these two datasets.
Diabetes was selected as the condition of interest
because it is commonly managed by general practitioners
(GPs). The Australian national BEACH study of general
practice activity reported an estimated 9.5% of patients at
GP encounters having type 2 diabetes and 0.9% type 1
diabetes (Britt et al., 2014). It is also significant in terms
of cost burden. Recent estimates put the annual cost of type
2 diabetes in Australia at around AUD6 billion with type 1
diabetes costing AUD570 million per year (Shaw et al.,
2012). Diabetic medications were the most studied pharmacological class in the last decade (Mamtani et al., 2014),
and diabetes is the most studied condition using data
obtained from patient EMRs (Dean et al., 2009).
Ideally, researching disease prevalence using EMD
would involve analyses of coded diagnoses extracted from
the designated “diagnosis” field of the patient’s EMR (Geraldine et al., 2012; Hwang et al., 2013). In reality (as
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explained above), diagnoses are not always coded (free text
may be employed) or entered in the designated field – or
recorded at all, and therefore are missing in data extraction.
In the absence of diagnostic labels and codes, pharmacological data have also been used as a proxy for a diabetes
diagnosis (Huber et al., 2014). Although the Anatomical
Therapeutic Chemical (ATC) classification (World Health
Organisation, 2009) groups together medications used for
diabetes, these may be prescribed for other conditions,
reducing their reliability as indicators of diabetes. For
example, metformin (ATC Code A10BA02) is commonly
prescribed for diabetes but can also be used to treat polycystic ovarian syndrome (PCOS) and impaired glucose tolerance (IGT). Diabetes prevalence may be over-estimated
if it is assumed that all ATC code A10 medications are
prescribed only for diabetes. Conversely, some patients
with diabetes may be missed if they are treated with nonpharmacological measures alone.
A combining of the diagnostic label and prescription
data has previously been used to ascertain the presence of
diabetes (Calvert et al., 2007; Chiang et al., 2014; Hasvold
et al., 2014; MedicineInsight, 2016). The World Health
Organisation defines a glycated hemoglobin (HbA1c) level
of 6.5% (48 mmol/mol) or greater as diagnostic of diabetes
(World Health Organisation, 2011). Even in the absence of
relevant diagnoses or prescriptions, an elevated HbA1c
implies diabetes.
In Australia, costs of GP consultations are subsidised
through the universal insurance scheme, Medicare. Via the
Medicare Benefits Schedule (MBS) (Australian Government Department of Health, 2014), a specific rebate item
number is available to GPs for performing diabetic annual
cycle of care (DACC). This involves a review of diabetic
management and treatment goals specifically for patients
with diagnosed diabetes. While claims data involving this
item number have previously been used to assess diabetes
management (Comino et al., 2015), no previous studies
have used these data to determine diabetes prevalence.
In Sweden, Rolandsson et al. (2012) demonstrated the
validity of the diagnosis of diabetes based on the information in general practice medical records (including the
coded diagnosis, pharmacological data, and records of
HbA1c results) (Rolandsson et al., 2012). However, we
have been unable to identify any previously published Australian studies that have attempted to validate data from
EMRs in the determination of a diabetes diagnosis.
Aim of this study investigates the validity of EMD for
estimating the prevalence of diabetes in general practice
patients by comparing data extracted from EMRs with prevalence data from patient-based sub-studies of the University
of Sydney’s national BEACH program (Britt et al., 2014).

Methods
The EMD set came from the ISPRN based at the University
of Wollongong. There were 40 general practices in the
ISPRN network when the project commenced, and a convenience sample of six member practices (chosen because
they varied in size and geographic location) was invited to
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Box 1. The EMD decision tree. EMD: electronic medical data.
Coded
diagnosis of
diabetes

Yes

Diabetes

No

Uncoded
diagnosis of
diabetes

No

HbA1c
diagnostic of
diabetes

No

Yes

Yes

No

Yes

Probably
not
Diabetes

Yes

No

Yes

Diagnosis of
IFG or IGT or
PCOS

DACC
performed

participate. All used Best Practice™ clinical software,
ensuring standard structure and terminology.
Researchers from both the University of Wollongong
and the University of Sydney met via teleconference to plan
the project method. Based on the literature review (above)
and the clinicians’ knowledge, the authors agreed on a set
of variables for inclusion in a data extraction query, in
addition to coded diagnoses, in case a coded diagnosis had
not been recorded.

EMD set
An SQL query was created to extract de-identified patient
demographic and medical data variables of interest: age;
sex; diagnosis of diabetes, PCOS, IGT, or impaired fasting
glucose (IFG; coded or uncoded, i.e. free text); diabetes
cycle of care plan (DACC); recorded HbA1c value of
6.5% (48 mmol/mol); prescription of metformin; and/or
prescription of other diabetes medications. The research
team (seven clinicians (four with PhD, one with masters
in clinical information systems and technology, and one
with masters in biostatistics) and one health information
manager (PhD in medicine (general practice)) determined
that this group of variables was the best indicator of diabetes if the record lacked the diagnosis label and, accordingly, created a “decision tree” (Box 1). Therefore, in the
absence of “diabetes” in a diagnosis label, the presence of
diabetes in the patient was inferred based on the “decision
tree” variables.
Best Practice software uses its own bespoke PYEFINCH
coding system. Codes identifying diabetes, PCOS, IGT, or
IFG were selected for the query, to allow subsequent exclusion of the last three if these had been incorrectly included
through use of metformin or other diabetes medication.
Metformin and other diabetes medications were identified

Takes
meormin
only

Yes

No

No

Other
diabetes
medicaons

by the presence in the EMR of a prescription for a medication classified to the ATC level A10 “Drugs used in Diabetes” (World Health Organisation Collaborating Centre of
Drug Statistics Methodology, 2009). Previous DACC was
determined by the presence of relevant MBS item numbers.
The query was designed and corrected as necessary to
ensure that the required variables were extracted. The
patient cohort consisted of active patients, defined as
patients who had had three or more encounters in the previous 2 years (Royal Australian College of General Practitioners, 2014). For this study, active patients at any one of
the participation practices were included from the 2 years
prior to January 1, 2015. Encrypted data were sent from
each practice to the investigators, by online secure transfer.

Comparison dataset: SAND sub-studies of the
BEACH program
The data used in the comparison analysis for validating the
prevalence estimate were collected through a series of Supplementary Analysis of Nominated Data (SAND) substudies of the BEACH program. BEACH was a continuous,
national, cross-sectional survey of Australian general practice activity. The BEACH methods have proven statistical
validity and reliability and have been described internationally as “the gold standard from consistent reporting”. The
methods are described in detail elsewhere (Britt et al.,
2014), but in brief, each year approximately 1000 randomly
sampled GPs were recruited. Each participant recorded
details of 100 encounters with consenting, unidentified
patients, on structured paper forms. Information was collected about the problem(s) managed for each patient, and
the management(s) provided (directly linked) for those
problems. Throughout the program, a series of SAND
sub-studies utilised the GP as an “expert interviewer” to
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Figure 1. Age distribution of patients in EMD records and in SAND sub-studies. EMD: electronic medical data; SAND: Supplementary
Analysis of Nominated Data.

record, in discussion with the patient, the aspects of patient
health that may not have been managed at the recorded
encounter. The SAND data are, therefore, patient-based
rather than encounter-based.
The SAND sub-studies were selected as the best dataset
for comparison because they were designed for active data
collection for the purpose of research. Thus, the presence or
absence of diabetes was the response recorded by the GP, not
inferred by variables suggestive of diabetes. Between
November 2012 and February 2015, 12 of the SAND substudies, each involving approximately 125 GPs, were used to
investigate the prevalence of diagnosed chronic conditions
for 30 of every 100 patients surveyed. GPs were asked to
record for the patient at each encounter, all their diagnosed
chronic conditions, including diabetes type 1 and/or diabetes
type 2, based on their knowledge of the patient, the patient’s
notes, and the patient’s knowledge of their own medical
conditions. The number of times the patient had seen any
GP in the previous 12 months was also recorded.

Statistical analyses
Using unadjusted SAND data, we estimated the prevalence
of diabetes among patients sampled at encounters. As
BEACH patients were sampled at GP encounters, the likelihood of being sampled is dependent on visit frequency.
Therefore, frequent attenders (older patients, patients with
one or multiple chronic conditions) are more likely to be
sampled than those who attend less frequently. To allow
fair comparison with EMD-derived results, the SAND
results were adjusted for the reported number of GP
encounters per year for each patient, allowing the creation
of prevalence estimates among the attending population.
This “active patient” sample was then age–sex standardised, by weighting the SAND data to match the age–sex
distribution of EMD patients. Missing data were excluded.

Both the BEACH program and the EMD project used a
cluster survey design (clustered around GP participants for
BEACH and around general practices for EMD). BEACH
analyses adjusted for the effect of cluster when 95% confidence intervals (CIs) were calculated around all point estimates, using survey procedures in SAS® 9.3 (Cary, North
Carolina, USA, in 2012). Similarly, a cluster-adjusted 95%
CI was calculated for the aggregated EMD diabetes prevalence estimate, using Microsoft Excel (v. 2013; Microsoft
Corporation, Redmond, Washington, USA). Differences
between EMD and adjusted SAND estimates were considered
statistically significant (p < 0.05) if the CIs did not overlap.

Ethics
The research study was approved by the Human Research
Ethics Committee (HREC) of the University of Wollongong/Illawarra Shoalhaven Local Health District (HREC
approval number HE13/484, November 21, 2013). Signed
consent was obtained from all practice principals involved
prior to data extraction, and downloaded patient data were
de-identified prior to extraction. The BEACH program and
all SAND sub-studies have ethics approval and oversight
by the HREC of the University of Sydney (HREC approval
number 2012-130, valid to Match 31, 2018).

Results
Five of the six ISPRN practices agreed to participate. Data
from these five practices resulted in a sample of 30,007
patients. The “date of birth” field was not completed for
39 patients (0.13%). For the remainder, the median age
was 47 years (interquartile range (IQR) 23–65). Persons
aged 65 years and over accounted for 25.6% of the sample
(Figure 1) and females for 56.4%.
In the BEACH study, of the 1500 GPs who were
recruited and sent recording forms containing the sub-
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Figure 2. Age distribution of patients: At BEACH encounters, at claimed MBS GP consult service items, and at encounters in the SAND
sub-studies. BEACH: Bettering the Evaluation and Care of Health; MBS: Medicare Benefits Schedule; GP: general practitioner; SAND:
Supplementary Analysis of Nominated Data.

study questions about diagnosed chronic disease and number of GP visits, 1172 returned completed questionnaires
(78.1%) for 35,162 GP-patient encounters. The “date of
birth” field was incomplete for 267 patients (0.76%). The
patient median age was 52 years (IQR 31–69), 32.5% being
aged 65 years and over, and 59.7% being female. The
SAND sub-studies were chosen for comparison because
they are nationally representative. Figure 2 shows the age
distribution of patients: at all BEACH encounters for 2013–
2014, for whom MBS GP consultation service items were
claimed through Medicare in 2013–2014, and at the
BEACH encounters where the SAND data were collected.
The greatest disparity in any age group (compared with the
Medicare distribution) is less than 2% points.
At the first step of the EMD diabetes prevalence model
(decision tree), there were 1700 patients with a coded diagnosis of diabetes, giving a prevalence of 5.7% based on this
variable alone. When all proxy variables were assessed,
further 253 patients were identified as probably having
diabetes, increasing the total number to 1953 and the prevalence to 6.5% (95% CI: 4.1–8.9; types 1 and/or 2 combined; Figure 3).
Each proxy variable contributed different proportions to
the 253 extra cases identified (13.0% of 1953). The freetext (uncoded) search for diabetes accounted for 29.6% of
the 253 additional cases, but the major contributor was the
prescription of metformin (47.0% of 253; Figure 4). Using
this process did not allow differentiation between types 1
and type 2 diabetes.
From the SAND data, we could estimate the prevalence
of types 1 and 2 diabetes separately, but for comparison
with the EMD dataset, these were combined. The combined
prevalence among sampled patients was 10.3% (95% CI:
9.9–10.6), active patients (i.e. adjusted for number of visits)

was 5.6% (5.3–5.8), and “age-sex standardised” active
patients was 6.7% (6.3–7.1). This 6.7% did not significantly differ from the EMD sample estimate above
(6.5%; 4.1–8.9; p ¼ 0.8, Satterthwaite method, equivalent
to t ¼ 0.21, df ¼ 33,123).

Discussion
This study tested the validity of EMD to estimate the prevalence of diabetes in general practice patients by comparing data extracted from EMRs with prevalence data
gathered as part of the national BEACH program. The
findings add to the ongoing debate about the usefulness
of EMD data for research in its current state (Hersh et al.,
2013). By recognising that GP data are often incomplete,
and by employing proxy variables where coded diagnoses
were not recorded, the EMD has produced a prevalence
estimate for diabetes that is not significantly different to
that yielded by a dataset of proven validity and reliability.
The fact that approximately 13% of diabetes cases were
not coded when a coding system was available in the software supports the need to foster ongoing efforts to improve
data quality. However, by compensating with proxy measures such as medications, free-text searches of other fields,
item numbers, and the consideration/exclusion of other
diagnoses, the usefulness of EMD can be improved, given
access to good SQL skills or designed-for-purpose data
extraction tools.
The results of this study also highlight that not all
proxies are equal. Individual variables, and the order in
which they are queried, add differing numbers of cases. For
example, the simple addition of “uncoded” free-text diagnoses of diabetes accounted for 29.6% of the additional
cases. The major contributor to additional likely cases
(47.0%) was the subgroup of patients taking metformin
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Figure 3. Diabetes prevalence using the EMD Decision Tree.
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%
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(48 mmol/mol)
DACC MBS Item Number/s

Meormin +/- other diabetes
medicaon/s
87.0

other diabetes medicaon/s;
no meormin

Figure 4. Contribution of coded diabetes and of proxy variables
(i.e. all variables except “coded diabetes”) to diagnosis count.

who had no (coded or uncoded) diagnoses of diabetes,
PCOS, or IFG and no HbA1c result. Metformin alone as
a search term may be associated with conditions other than
diabetes (such as PCOS, impaired fasting glycaemia, or
weight gain) and may thus lead to false positives.
Our “step-wise” use of metformin minimises the risk of
inaccuracy, by excluding potential false positives before
the metformin criterion is applied. Despite this approach,
many EMD studies may require manual review of at least
a representative sample of records, to further clarify the
accuracy of the results. This is a consideration for future
studies. In contrast, the use of non-metformin oral hypoglycaemic agents and of insulin is strongly correlated with
diabetes, and the number of additional cases is very likely
to be accurate.
The design of this method involved clinicians and academics who understand how diabetes is managed in general
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practice, which allowed the creation of a tool most likely to
reduce false negatives. The designers felt confident that the
proxies selected for an investigation of diabetes should result
in very few missed cases. These proxies, however, were not
able to identify type 1 as distinct from type 2, and possibly
included gestational diabetes or diabetes insipidus, where
either the term “diabetes” or the proxies were searched as
free text. Unless there was some clear indicator that the
diabetes (actual or inferred) was other than types 1 or 2, it
will not have been excluded. Another consideration in using
medications as proxy variables to distinguish between diabetes types is the degree to which the use of these medications overlaps – metformin is used to treat type 2 diabetes,
but may also be used for gestational diabetes. Insulin can no
longer be considered a point of differentiation between types
1 and 2 as the progression of type 2 diabetes increasingly
involves the eventual requirement for insulin (Diabetes Australia, 2015). These diagnosed conditions were clearly differentiated using the traditional research methods employed
in the SAND sub-studies of BEACH.
While undertaken in the Australian setting, this work
has international implications. Studies from the United
Kingdom (Calvert et al., 2007; Majeed et al., 2008; Muller,
2014; Shephard et al., 2011) and the United States (Hersh
et al., 2013; Kamal et al., 2014) have reported advantages
of using EMR data for research, but in all cases have also
acknowledged the weaknesses of these data and the impact
on data quality. There is evidence that different types of
variables may have different GP completeness-ofrecording rates. This may affect the capacity to produce
prevalence data when investigating other diseases or population sub-groups. For example, demographic variables
such as age and sex have a high completion rate in EMRs.
It is obvious when a “date of birth” or “age” is missing as
all patients have one. For both datasets in this study, the
proportion of missing data for the recorded “date of birth”
was clear – 267 patients (0.76%) in the SAND sample and
39 patients (0.13%) in the EMD sample. However, other
variables such as “smoking status” may be considered differently. If the GP considers the patient’s smoking status to
have a clinical bearing only if the patient does smoke, this
may influence the decision to complete this variable for
nonsmokers – which decreases the variable’s reliability.
In a previous comparison of the EMD with BEACH data,
there was a significant difference (p ¼ 0.03) in proportion
of current smokers between the two datasets, possibly
influenced by the high proportion of missing “smoking
status” data (17.6%) in the EMD sample compared with
BEACH data (1.8%) (Barnett et al., 2017).
Other researchers have commented on the differing
“value” of variables and its effect on completeness. Mazza
et al. (2016) suggested that “because the primary use of the
data is to inform the clinical care of a patient, only data that
serve a clinical purpose have a high degree of validity and
reliability. Therefore, items such as Aboriginality are not
necessarily well recorded.”
A number of authors in the United States and the United
Kingdom (e.g. Kamal et al., 2014; Muller, 2014) have
acknowledged that some variables are more complete than
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others and many factors will influence this aspect of data
quality. Muller (2014) suggests that the health system of a
country may influence prescribing behaviour as in some
cases, a medication that is available without a prescription
may be advised for some patients and prescribed for others,
depending on their income and circumstances. In the US
study by Kamal et al. (2014), the researchers reported
“incomplete data sets for certain patient characteristics
(race, marital status, and employment” and “the EMR data
did not contain information related to lifestyle measures
such as exercise and diet.” This latter exclusion will also
have had an impact on the current study as any patients who
did not have a diabetes label acknowledging their diagnosis
may have been missed unless other proxy variables captured them. A further consideration when selecting proxy
variables is the approximately 24% of Australian general
practice patients with type 2 diabetes who have their condition managed with diet and exercise only (Family Medicine Research Centre, University of Sydney, 2012). These
patients would not be included in any prevalence estimate
reliant on medication alone as a proxy for identification.
Although there is a consensus that reliable data are
essential – for clinician and patient education, for patient
safety, for financial planning and resource allocation –
what should be acknowledged is that EMRs were designed
for the clinician to keep track of their patient’s care, not as a
research tool. GPs are time poor, and the variables being
presented to them for recording patient information in currently available clinical software programs are numerous.
The computer already imposes on the time a GP might
otherwise give to the patient (Dowell et al., 2013; Haywood
et al., 2015; Pearce et al., 2011), so there is a selection
process occurring that meets the primary objective, that
is, the care of the patient. Many GPs may not think it
important to “patient care” to record the indication associated with a medication or a test in a specified area – they
know why the script was given or the test ordered – and this
absence limits the capacity of EMRs to produce a reliable
prevalence estimate. Where no diagnosis is recorded and a
medication or test could be for a number of possible indications, the method developed for the EMD sample in this
diabetes investigation would be far less reliable when
applied to other conditions. Data linkages in EMRs would
resolve many of these problems with identification of diagnoses. At present, all research based on data extraction
from EMRs faces the same problem. Assessing the extent
of missing data would allow the measurement of data quality but for many variables, the proportion of missing data is
not known and the validity and reliability of any calculations using an unknown denominator cannot be estimated.
“The completeness and accuracy of data entry relies
mainly on the enthusiasm of family practitioners” (Majeed
et al., 2008). This statement is highly appropriate to this
investigation. While these results have provided some evidence of the proportion of diabetes being missed with current extractions that rely on coded diagnosis fields only
(13.0%), it should be acknowledged that the five participating practices contributing to the EMD set consist of GPs
who are highly “data conscious” and because of this
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awareness, and their ongoing quality improvement activities, EMD from a different set of practices may have produced a different result.
This work is, therefore, both enlightening and valuable.
It is the first attempt by any Australian researchers to validate the data from their patient EMRs in this manner, to
assess its fitness as a research tool. The results have shown
that while it may be a more complex approach, the use of
proxy variables can improve the usefulness of EMD as a
research tool, in some circumstances. The result was promising with diabetes and the researchers had planned a
series of investigations on other chronic diseases using the
BEACH and SAND sub-studies for validation. The
BEACH datasets, while not electronic, have been proven
repeatedly to be valid, reliable representations of general
practice activity and are, therefore, highly appropriate datasets to employ for this purpose. Given the BEACH project
has now ceased, the work undertaken for this study is very
timely – it will not be easy to find a comparable dataset of
its calibre in the future.
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